PRE-NAPLEX
1. How do you calculate RRR?
You have these values:
Zoledronic acid (risk of fracture): 8.6%
Placebo (risk of fracture): 13.9%: 1) Calculate the RR (% Tx/% Control)
8.6%/13.9% = 0.6187
2) Calculate RRR: (1 - RR)
1 - 0.6187 = 0.38
RRR: 38%
Zoledronic Acid treated patients where 38% less likely to have a fracture than
placebo treated patients.
2. You have a case: The primary endpoint for a fracture was lower with Zole-
dronic acid compared to placebo (8.6% vs 13.9% respectively); p=0.001; RR=
0.62 [95% CI, 0.5 to 0.84]
What probability does the p-value tell you?: The p-value tells you that the
probability of rejecting a true null hypothesis is 0.1%
RxPrep: When p-value is < 0.001 and alpha is 0.05:
99.9% probability (confidence) that the conclusion is correct; less than 0.1% chance
it's not.
NOT SURE OF THIS DAMN QUESTION.
3. What does Intention to Treat tell you?: It includes data for ALL patients origi-
nally allocated to each treatment group (active and control) even if the patient did
not complete the trial according to the study protocol (ex. non-compliance, protocol
deviations, study withdrawal)
4. You have a study with the mean age of 75 (SD +/- 10).
What percentage describes the proportion of study subjects between 65 to 85
years of age in this study?: if it forms a "gaussian" or "normal" curve
68% of values fall within 1 SD (65 to 85)
95% of values fall within 2 SD (55 to 95)
5. You have a patient on the below orders:
Morphine 10mg IV/Hr
Morphine 0.5mg IV Q 20 min prn via PCA
if they get the max amount of doses of PCA, how many mg of morphine will
they receive over 12 hours?: 138 mg of morphine
1/8
, PRE-NAPLEX
10mg x 12 = 120mg
12hr x (60min/hr) x (0.5mg/20 min) = 18mg
120 + 18 = 138mg
6. How would you educate Mr. Blaine on using his peak flow meter?: the
measurement takes into account the patient's height, gender, & age
Patients should measure their personal best by taking peak flow readings BID (AM +
PM) for 2-3 weeks. The highest reading that occurs most frequently is their personal
best
TECHNIQUE:
use QAM upon awakening before the use of asthma meds
Stand up straight, exhale comfortably
Blow out as hard and as fast as possible. Write down PB
ZONES:
green zone: (> 80-100% of personal best) - CLEAR!
yellow zone:(50-80% of personal best) - "caution" pt intervention required based on
"action plan"
RED ZONE (<50% personal best): "MEDICAL ALERT" --> ED.
7. What vaccines are recommended in patients with Sickle Cell Disease?: Rou-
tine childhood series:
1. Haemophilus Influenzae type B (Hib)
2. Pneumococcal conjugate (PCV13, Prevnar)
Additional vaccines due to functional asplenia:
1. Meningococcal conjugate series plus routine boosters
2. Meningococcal serogroup B (Bexsero, Trumeba)"
3. Pnuemococcal polysaccharide (PPSV23, Pneumovax 23)""
4. Pnuemococcal conjugate (PCV13, Prevnar) x 1 in ANY patient > 6 y.o. of age if
never recd as part of routine childhood
": at age > 10 y.o.
"": at age > 2 y.o, booster 5 years later and at age > 65.
remember you don't want to give pnuemovax before 2 y.o. due to antibodies - they
will not produce a good response.
8. Describe Sickle Cell Anemia: Group of inherited RBC disorders resulting from
a genetic mutation in the genes that encode hemoglobin
2/8
1. How do you calculate RRR?
You have these values:
Zoledronic acid (risk of fracture): 8.6%
Placebo (risk of fracture): 13.9%: 1) Calculate the RR (% Tx/% Control)
8.6%/13.9% = 0.6187
2) Calculate RRR: (1 - RR)
1 - 0.6187 = 0.38
RRR: 38%
Zoledronic Acid treated patients where 38% less likely to have a fracture than
placebo treated patients.
2. You have a case: The primary endpoint for a fracture was lower with Zole-
dronic acid compared to placebo (8.6% vs 13.9% respectively); p=0.001; RR=
0.62 [95% CI, 0.5 to 0.84]
What probability does the p-value tell you?: The p-value tells you that the
probability of rejecting a true null hypothesis is 0.1%
RxPrep: When p-value is < 0.001 and alpha is 0.05:
99.9% probability (confidence) that the conclusion is correct; less than 0.1% chance
it's not.
NOT SURE OF THIS DAMN QUESTION.
3. What does Intention to Treat tell you?: It includes data for ALL patients origi-
nally allocated to each treatment group (active and control) even if the patient did
not complete the trial according to the study protocol (ex. non-compliance, protocol
deviations, study withdrawal)
4. You have a study with the mean age of 75 (SD +/- 10).
What percentage describes the proportion of study subjects between 65 to 85
years of age in this study?: if it forms a "gaussian" or "normal" curve
68% of values fall within 1 SD (65 to 85)
95% of values fall within 2 SD (55 to 95)
5. You have a patient on the below orders:
Morphine 10mg IV/Hr
Morphine 0.5mg IV Q 20 min prn via PCA
if they get the max amount of doses of PCA, how many mg of morphine will
they receive over 12 hours?: 138 mg of morphine
1/8
, PRE-NAPLEX
10mg x 12 = 120mg
12hr x (60min/hr) x (0.5mg/20 min) = 18mg
120 + 18 = 138mg
6. How would you educate Mr. Blaine on using his peak flow meter?: the
measurement takes into account the patient's height, gender, & age
Patients should measure their personal best by taking peak flow readings BID (AM +
PM) for 2-3 weeks. The highest reading that occurs most frequently is their personal
best
TECHNIQUE:
use QAM upon awakening before the use of asthma meds
Stand up straight, exhale comfortably
Blow out as hard and as fast as possible. Write down PB
ZONES:
green zone: (> 80-100% of personal best) - CLEAR!
yellow zone:(50-80% of personal best) - "caution" pt intervention required based on
"action plan"
RED ZONE (<50% personal best): "MEDICAL ALERT" --> ED.
7. What vaccines are recommended in patients with Sickle Cell Disease?: Rou-
tine childhood series:
1. Haemophilus Influenzae type B (Hib)
2. Pneumococcal conjugate (PCV13, Prevnar)
Additional vaccines due to functional asplenia:
1. Meningococcal conjugate series plus routine boosters
2. Meningococcal serogroup B (Bexsero, Trumeba)"
3. Pnuemococcal polysaccharide (PPSV23, Pneumovax 23)""
4. Pnuemococcal conjugate (PCV13, Prevnar) x 1 in ANY patient > 6 y.o. of age if
never recd as part of routine childhood
": at age > 10 y.o.
"": at age > 2 y.o, booster 5 years later and at age > 65.
remember you don't want to give pnuemovax before 2 y.o. due to antibodies - they
will not produce a good response.
8. Describe Sickle Cell Anemia: Group of inherited RBC disorders resulting from
a genetic mutation in the genes that encode hemoglobin
2/8
